Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sugemalimab - CStone Pharmaceuticals/EQRx

Drug Profile

Sugemalimab - CStone Pharmaceuticals/EQRx

Alternative Names: Cejemly; CS-1001; Sugelimab; WBP-3155; Zegema; Zegemet; Zegemex; ZEJIEMEI

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CStone Pharmaceuticals
  • Developer Bayer; CStone Pharmaceuticals; EQRx
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Oesophageal cancer
  • Registered Gastric cancer
  • Preregistration Extranodal NK-T-cell lymphoma
  • Phase III T-cell lymphoma
  • Phase II Hodgkin's disease
  • Phase I/II Liver cancer; Solid tumours
  • No development reported Small cell lung cancer

Most Recent Events

  • 15 Mar 2024 Registered for Gastric cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Second-line therapy or greater) in China (IV)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top